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ARTICLE OPEN
Adherence to guideline recommendations for asthma care in
community pharmacies: actual and needed performance
Esther Kuipers 1,2, Michel Wensing 1,3, Elaine Wong-Go 4, Bernard J. G. Daemen 4, Peter A. G. M. De Smet 1,5 and
Martina Teichert 6
Pharmaceutical care guidelines aim to provide recommendations for pharmaceutical care, reduce unwanted pharmacy practice
variation and ultimately improve the quality of healthcare. This study evaluated community pharmacists’ adherence to
recommendations for the provision of care to asthma patients with ﬁrst dispensing and follow-up reﬁll encounters in The
Netherlands. Data were pharmacists’ self-assessment of adherence to guideline recommendations, independent observations of
dispensing encounters and a nationwide questionnaire on pharmacists’ views on the desirable (clinical) necessity of applying
guideline recommendations to their patient population. The 21 pharmacists who performed self-assessment judged their
adherence concerning inhalation instructions as high. The lowest scores were reported for recommendations to collect additional
information on the type of lung disease and for asking patients’ expectations, wishes and concerns. Sixty-eight dispensing
encounters were observed. In 83% of the 35 ﬁrst dispensing observations, inhalation instruction was provided. This percentage was
lower (62%) at reﬁll dispensings. During all encounters, pharmacy staff seldom explored patients’ perceptions or responded to
patients’ expectations, wishes and concerns. One hundred and four pharmacists completed the feasibility questionnaire.
Pharmacists judged that all patients should receive inhalation instruction at ﬁrst dispensing. They regarded it necessary to check on
patients’ expectations, wishes and concerns regarding the treatment for only up to 70% of the patients. More efforts on guideline
implementation are needed, especially on follow-up dispensings and on gaining relevant information from patients and other
healthcare professionals. Pharmacists still have opportunities to grow in applying a patient-tailored approach and exploring
patients’ individual needs, rather than providing practical information.
npj Primary Care Respiratory Medicine           (2019) 29:26 ; https://doi.org/10.1038/s41533-019-0139-5
INTRODUCTION
Pharmaceutical care guidelines aim to describe optimal pharma-
ceutical care (i.e. timely and appropriate patient-centred care,
tailored to the individual patient’s needs), the care patients and
stakeholders can expect from pharmacists and ultimately improve
the quality of healthcare by providing pharmacists with recom-
mendations that reﬂect prevailing knowledge.1,2 The Royal Dutch
Association for the Advancement of Pharmacy (KNMP) has
recently developed a new guideline for asthma care.3 The
guideline recommendations address pharmacotherapy in asthma,
multidisciplinary cooperation with other healthcare professionals
(e.g. general practitioners (GPs) and lung specialists), the
dispensing process, patient monitoring and counselling. By
providing pharmaceutical care to patients with asthma, the
pharmacist can help them to achieve treatment goals, e.g.
improvement of disease control and reduction of asthma
symptoms, exacerbations and medication-related side effects.4–
10 The pharmacists and their team have an important role in
medication counselling, especially at the encounters during the
dispensing moments in daily practice. They have good opportu-
nities to inform and counsel patients and support them in using
their medication properly.11–14 After treatment initiation with a
pharmaceutical encounter during the ﬁrst dispensing (FD) of
asthma maintenance medication, patients return to the pharmacy
for the ﬁrst reﬁll (second dispensing (SD)), followed by general
reﬁll dispensings (RDs). The guideline contains 23 recommenda-
tions for pharmaceutical encounters (14 for FDs, 7 for SDs and 2
for RDs) and emphasises the importance of patient counselling.
Especially, information on using the inhaler correctly is essential,
because incorrect inhaler technique and non-adherence to
therapy are recognised as major factors in poorly controlled or
uncontrolled asthma.15–17 The information during the FD is
targeted to the starting patient, focussing on the inhalation
instruction, tailored information to encourage good drug use and
the appropriateness of the inhaler for the individual patient. The
guideline recommendations regarding SDs focus on patients’ ﬁrst
experiences with the medication (e.g. inhalation technique, effect,
side effects).
The period between the ﬁrst and the second prescription is
decisive for the start and subsequent adherence to the medication
scheme.11–14 During the consultation of a healthcare professional,
there are two needs that have to be met: ‘the need to understand’
(to know and understand what is the matter) and ‘the need to be
understood’ (to know that he/she has taken seriously and
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accepted).18 To meet both pharmacists’ and patients’ needs, the
pharmacist should alternate information-giving and information-
asking during patient encounters.18 Regarding pharmaceutical
encounters in general, the guideline states that these are ideally
based on reciprocal trust and shared decision-making, according
to the Calgary–Cambridge model.19,20 Good communicative skills
of pharmacists can encourage active patient participation, which
is likely to be associated with positive health outcomes.21–23
However, an effect on clinical practice only can be attained by
successful implementation of the guideline recommendations into
daily routines.24–26 There are several success factors and barriers
that may enhance or impede the implementation of the
recommendations in daily practice.1,24–30 The guideline develop-
ment follows a standardised process and consecutively involves
drafting the text based on the existing literature and expertise,
early assessment in daily practice, asking experts and organisa-
tions for feedback and accreditation and publication. Therefore,
before guideline authorisation, a practice test on the actual
situation and assessment of the feasibility for implementation has
to be performed. In previous studies, adherence to different
asthma care guidelines was mainly assessed in surveys by self-
assessment of the healthcare professionals29,31 or by retrospective
extraction from patient records.32,33 However, it is obvious that
not all care-related activities are documented completely and
uniformly, and studies have shown that observation in daily
practice also can provide meaningful additional information.34,35
Furthermore, it may not always be necessary or even wanted to
apply the guideline recommendations to all patients individually.
Thus the expectation of ﬁnding complete follow-up of all
guideline recommendations for the patient population cannot
be met from a patient-centred approach. The estimation of
healthcare providers on the scores for their population can help to
achieve a realistic perspective on the feasibility of adherence to
guideline recommendations in clinical practice.
In this study, we aimed to assess the actual performance of
community pharmacists regarding recommendations for different
pharmaceutical encounters from the concept asthma care guide-
line, using (1) pharmacists’ self-assessment, (2) real-time observa-
tions and (3) a questionnaire on the scores to be achieved on
population level for guideline recommendations with regard to
individual patient needs.
RESULTS
Basic pharmacy characteristics
All pharmacists from 21 community pharmacies reported that
they worked according to a certiﬁed quality management system.
Overall, they reported that they cooperated well with GPs in
structured pharmacotherapy audit meetings. A consulting room
was available in all pharmacies. The mean team size was 1.71 (SD
0.83, range 0.85–3.4) fulltime equivalent (FTE) pharmacists and
8.11 (SD 3.27, range 4–15) FTE pharmacy assistants.
Self-assessment
Twenty-one pharmacists completed the self-reported adherence
questionnaire on the implementation of the guideline recom-
mendations regarding the three types of dispensing encounters.
Regarding the FD encounters, for 5 out of 14 items, the majority
(≥16 of the 21 pharmacists) reported to be 80–100% adherent
(Table 1). These included checking the appropriateness of the
inhaler for the patient, checking if inhalation instruction already
had been provided, giving inhalation instruction if necessary,
using the protocols of the Lung Alliance Netherlands (LAN) for the
instruction and making sure that all information was understood
by the patient. Nine recommendations showed lower adherence
rates, with the lowest scores for veriﬁcation of the type of lung
disease; checking patients’ expectations, wishes and concerns
regarding the treatment; and making appointments for follow-up
consultation or repeated inhalation instruction.
During the SD encounters, the highest score was found for
checking whether the patient had understood the information.
The lowest scores were reported for checking patients’ expecta-
tions, wishes and concerns regarding the treatment and discuss-
ing agreements from the FD encounter (10 and 8 pharmacists do
this in 0% to 20% of the situations, respectively).
Regarding the RD encounters, 17 out of the 21 pharmacists
reported that they check patients’ medication experiences in
<50% of the situations.
Real-time observations
Sixty-eight individual pharmaceutical encounters were observed:
35 FD, 13 SD, and 20 RD encounters (Table 1). For 3 out of the 14
items regarding the 35 FD encounters, the observed adherence
rate was at least 80%. This included providing inhalation
instruction (83%), using the LAN protocols for the instruction
(91%) and, at the end of the counselling, making sure that all
information was understood by the patient (97%). For 4 items, the
adherence rates were between 60% and 70%, including checking
the appropriateness of the inhaler, assessing whether the patient
had already received inhalation instruction from another health-
care provider, checking what was known about the prescribed
medication and providing tailored advice. The lowest adherence
rates (3%) were found for the recommendations on appointments
for a SD consultation for repeating the inhalation instruction.
Checking patients’ expectations, needs and concerns regarding
the treatment (23%) and documenting all relevant ﬁndings and
follow-up appointments (14%) were also not common during the
FD observations. During the SD encounters, adherence rates
remained low (15%) with respect to these two recommendations.
Patients’ experiences and possible problems were always (100%)
discussed in SD encounters and in 40% of the RD encounters.
During the RD encounters, active screening on suboptimal use
of inhalation medication (e.g. overuse of short-acting beta-agonist
or maintenance medication non-adherence) was observed in 25%
of the follow-up reﬁll encounters.
Necessity questionnaire for adherence to guideline
recommendations at the population level
One hundred and four expert pharmacists (response rate 5.4%)
completed the questionnaire regarding the expected necessity of
adherence to the 23 recommendations at the population level
regarding the needs of individual patients in daily practice
(Table 1).
The highest scores (adherence up to 90%) were reported on the
recommendations regarding checking the appropriateness of the
inhaler, using the LAN protocols, giving inhalation instruction and
checking whether the patient understood the information.
The highest rate of consensus was for providing inhalation
instruction. The lowest rate of consensus was for the FD
recommendations regarding appointments for follow-up consul-
tations (median score 70%, interquartile range (IQR) 40–80) and
documenting the relevant ﬁndings (median score 80% IQR
60–100) and for the SD encounters for checking the inhalation
technique (median score 80%, IQR 60–100) and discussing
agreements from the FD encounter (median score 70%, IQR
52.5–90).
Overall, for 3 out of the 23 recommendations, the performance
observed in daily practice reached the desired score. First, using
the LAN protocols was observed in 91.4% of the FD encounters
(necessity score of 90%). Second, checking whether the patient
has understood the information was reported to be necessary for
at least 90% of the patients, and this was observed in 97.1% of the
FD encounters. Patient’s experiences with the medication and
possible problems were asked in 100% of the SD encounters
E. Kuipers et al.
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(necessity score of 80%). However, the pharmacists seemed to
have underestimated their performance; the self-reported adher-
ence was lower for these recommendations.
The largest differences in observed adherence and desired
scores were found for the following recommendations: making an
appointment for follow-up consultation in the pharmacy (2.9%
observed vs. 70% desired); agreeing with the patient on
subsequent counselling with inhalation instruction (2.9% vs.
70%); noting all relevant ﬁndings and follow-up appointments
(14.3% vs. 80%); checking patients’ expectations, wishes and
concerns regarding the treatment (15.4% vs. 70%); and paying
attention to the possibilities for follow-up consultation (15.4%
vs. 70%).
DISCUSSION
This study provided insights into the actual situation and
assessment of the feasibility of implementing recommendations
from the concept asthma care guideline for community pharma-
cies in daily practice.
Overall, adherence to the guidelines varied across recommen-
dations as well as pharmacists. There were similarities but also
differences between the self-reported adherence, real-time
observations and desired scores. This study showed that
pharmacy staff members were focussed on providing relevant
information during the FD encounters, but the information was
less comprehensive during RDs. First reﬁlls were not always
recognised and acted upon, and when there were no appoint-
ments made after the FD, patients were possibly not aware of the
opportunity for additional care activities.
To fulﬁl pharmacists’ and patients' needs, the roles of
information-giving and information-seeking have to be alternated
during encounters. However, pharmacy assistants rarely explored
patients’ perceptions or asked about expectations, wishes and
concerns. This has also been shown in earlier studies; pharmacy
staff in community pharmacies generally provided practical
information and seldom discussed patient’s preferences and
perceptions about prescribed medications.11,14 Speciﬁcally, the
topics for repeated dispensings were rarely discussed and the
pharmacy staff members did not stimulate patients to ask
questions, which is also found in other studies.14,21,36–39 In
addition, the observers mentioned that, although in the majority
of the encounters pharmacists checked whether the patient had
understood the information, this was asked in a rhetorical way
rather than with an open question.
The results of the self-assessment and observations were added
to by our questionnaire survey. In general, there was a lack of
consensus among pharmacists. Clearly, there are some recom-
mendations that should be followed for the large majority of the
patients, for example, providing inhalation instruction or checking
whether patients had understood all information and the
appropriateness of the prescribed inhaler. However, pharmacists
reported lower feasibility scores for the majority of recommenda-
tions. Some of these recommendations (e.g. making appointments
for follow-up consultations or addressing service possibilities)
could be considered as optional, dependent on patients’ needs.
To improve patient outcomes, it is important to apply such a
patient-tailored approach and adapt the provided care to the
needs of the individual patient.15,40,41 Earlier studies have shown
that patients with chronic conditions have a need and a desire for
pharmacist counselling about new medications and that providing
patients with appropriate, tailored information has the potential to
improve medication adherence.42–44 However, to apply a patient-
tailored approach, it should be even more important to recognise
those needs in daily practice.
In this study, pharmacists reported in the questionnaire that
checking patients’ expectations, wishes and concerns regarding
the treatment was desirable in just 70% of the patients, but during
the observations, the score was much lower (22.9% for FD, 15.4%
for SD). Apparently, pharmacists are still used to a protocol-driven
way of providing information. However, to extend the traditional
role of the pharmacist towards the provision of patient-centred
pharmaceutical care, pharmacists should focus more on discussing
patient’s preferences, perceptions and needs rather than provid-
ing practical information. After all, it is difﬁcult to provide patient-
centred care when the type of lung disease (and consequently the
guideline that should be applied) is not known or when patients’
needs are not explored.
This study was a small-scale assessment of adherence to
guidelines in daily practice, combining observed practice and
reported intention regarding the adherence of guideline recom-
mendations. The independent observers considered the imple-
mentation of the guideline from a theoretical perspective, and the
trained and educated pharmacists were experienced in working
according to the guidelines in daily practice. This study was a ﬁrst
step towards evaluating guideline adherence and facilitating
further research that explores barriers for poor adherence.
There are some limitations to our study. First, the self-
assessment and observations were conducted in a small,
convenience sample of 21 pharmacies; however, their character-
istics did not differ from the national data.45 Second, the real-time
observations were performed at single moments (‘snapshots’),
which may have led to bias. However, all pharmacists were
experienced in pharmacy practice research and education and
were open to critical self-reﬂection. Third, the pharmacists were
aware that they were being observed and thus the performances
noted may have been better than normal performances. Conse-
quently, the potential for improvement in clinical practice may be
even higher for pharmacies in The Netherlands. Finally, because
the feasibility questionnaire was not validated beforehand, some
pharmacists might have experienced difﬁculty in comprehending
the instruction or the language used.
The guideline recommendations are formulated for the best
quality of care to be provided from actual knowledge. With
subsequent implementation of these recommendations, it is
expected that pharmaceutical care will be improved. In conclu-
sion, this study showed that, for a select group of leading
pharmacists, performance on information supply was high and
performance in exploring individual patient’s needs was low. More
efforts on guideline implementation are needed, especially on
follow-up dispensings and on gaining relevant information from
patients and other healthcare professionals. These results indicate
that more effort is needed to change the role of the pharmacist
from a professional who dispenses practical information to that of
a patient-tailored coach during medication use, according to the
guideline recommendations. More research is needed to explore
the barriers in clinical practice to change the behaviour of
pharmacists and technicians.
METHODS
Ethical approval
The study protocol was approved by the Ethical Committee of the
Radboud UMC Nijmegen (approval number: 2018–5057). We have
complied with all relevant ethical regulations.
Design
This observational study consisted of several elements: (1) pharmacists’
self-assessment of adherence to guidelines, (2) real-time observations of
adherence to guidelines in daily practice, and (3) a nationwide
questionnaire on pharmacists’ assessment of the necessity to follow the
recommendations at a population level.
E. Kuipers et al.
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Setting
A convenience sample of 21 community pharmacies in The Netherlands was
available for the self-assessment and real-time observations. During their
second year of master’s education in the University of Leiden, 21 pharmacy
students followed their internship in community pharmacies, under the
supervision of practising pharmacists who were specialised in community
pharmacy and were trained to supervise students. Before the start of their
internship, the students were educated in asthma symptoms (e.g. shortness
of breath, wheezing sound when exhaling), treatment and pharmaceutical
care according to the professional guideline. Additionally, they received a
brieﬁng and written instructions about their role of observers in the research
project. All pharmacists verbally agreed to participate in this study as part of a
practical assignment during the internships.
Pharmaceutical care in community pharmacies in The Netherlands has
been previously described in detail.13,46 Because most patients in The
Netherlands attend a single community pharmacy, pharmacists usually
possess the complete medication histories of their patients.47,48 Commu-
nity pharmacists and GPs had regular structured pharmacotherapy audit
meetings since 1990. In these local meetings, they make agreements on
pharmacotherapy based on national guidelines to improve prescribing and
dispensing of drugs.49,50
Guideline recommendations
The researchers selected the 23 guideline recommendations for pharma-
ceutical encounters (14 for FDs, 7 for SDs and 2 for RDs) from the concept
asthma guideline. Dispensings are deﬁned as FD when there was no
dispensing of the same medication in the year before. All further following
dispensing encounters after SD were deﬁned as RDs.
During the RDs, the guideline recommends discussing patients’
experiences and possible problems, if necessary. After patients had been
using the medications for a period of time, the pharmacist was advised to
screen the patients on drug therapy-related problems and suboptimal
medication use (e.g. overuse of rescue mediation, underuse of main-
tenance medication, inappropriate inhaler use or non-adherence) during
the encounters or by clinical decision support systems.51
Measures
For each of the 23 recommendations, the pharmacists answered the self-
assessment questionnaire on a Likert scale with the options: ‘we do this in
0–20% of the situations’, ‘we do this in 20–50% of the situations’, ‘we do
this in 50–80% of the situations’, and ‘we do this in 80–100% of the
situations’. Pharmacy characteristics (e.g. team size and the availability of a
consulting room) were collected.
Each student performed real-time observations of pharmaceutical
encounters by the pharmacy staff (both pharmacists and pharmacy
assistants) in daily practice during the internship. They noted their
observations using a standardised scoring list with ‘yes’ and ‘no’ options for
each of the 23 selected recommendations. In addition, they were invited to
reﬂect freely on their personal observations, answering the question ‘what
did you notice in this encounter?’ All students were educated on asthma
symptoms, the medications and the guideline recommendations. They
received additional training on the use of the checklists and instructions to
observe at least two dispensing encounters in daily practice. They were
independent observers and did not intervene.
All pharmacists in The Netherlands were invited to complete a
questionnaire regarding the necessity to follow the 23 selected recom-
mendations at the population level. They were asked to score the
minimum level (%) of adherence for each recommendation. To determine
this, pharmacists were asked to consider the need to apply certain
recommendations (e.g. do all patients need inhalation instruction, do all
patients need a repeated instruction) only as they pertain to individual
patients and to assume that all organisational preconditions (e.g. time,
incentives, skills of the pharmacy staff, computer support) were met. They
answered questions ‘for which minimum percentage of patients should
this recommendation be ideally followed for optimal implementation of
this guideline recommendation in clinical practice?’ on a 10-point Likert
scale with 10 categories: 0–10% of the patients, 11%–20%, 21%–30%, etc.
An e-mail invitation to participate in the survey was sent to 1936
community pharmacies in The Netherlands. Non-responders were sent a
reminder 1 week later. The questionnaire was distributed nationwide to
give all pharmacists the opportunity to share their opinions, but
pharmacists from the special interest group on lung diseases from the
KNMP and the pharmacy practice network were speciﬁcally invited to
complete the questionnaire. Together with the questionnaire, the
respondents received an instruction to focus on the desirable (clinical)
necessity for the patients and not on the practical (organisational)
feasibility in the pharmacy.
Data analysis
Data from the self-assessment and observations were documented in
Microsoft Word 2010. Descriptive statistics were used. For the necessity
questionnaire, we reported the upper value of the category as scored by
the pharmacists. Depending on the type of variable, the measures of
dispersion were analysed using median and IQR for non-normally
distributed variables and mean and SD for the normally distributed
variables. All analyses were performed using IBM Corp SPSS statistics,
Chicago IL, USA, version 25.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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